Mounjaro, Zepbound can help with weight loss in people with long-term obesity

Mounjaro, Zepbound can help with weight loss in people with long-term obesity

No matter how long a person has struggled with obesity or weight issues, weight loss medications like Mounjaro and Zepbound, which contain the ingredient trizepatide, can help them lose weight and decrease their waist circumference. Research on this topic will be presented at the European Congress on Obesity in Venice, Italy, in May of this year. The results have not yet been released in a peer-reviewed publication. The U.S.A. The FDA approved Mounjaro in 2022 to treat type 2 diabetes, and Zepbound in 2023 to help adults who have a body mass index (BMI) of over 30 or over 27 and at least one weight-related comorbidity manage their weight.

A bariatric surgeon and the medical director of the MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in California, who was not involved in the study, stated that the results are not shocking. These drugs are made to help you lose weight by interacting with your hormones. Throughout the study, they performed as intended. Although providing patients with a non-surgical option is a good idea, tirzepatide has certain drawbacks. According to Ali, Medical News Today, people need to take the medication consistently for it to be effective. If they haven’t taken the time to examine and alter their eating and lifestyle habits while taking the medication, the weight may return when they stop taking it. According to a 2023 study, after taking medication for 36 weeks, those who were switched to a placebo gained 14% of their original weight back. Five percent more of their body weight was lost by those who continued taking the medication.

In addition, insurance frequently does not cover the medication. The medication does have some side effects, but they are limited to mild nausea, vomiting, and constipation. To minimize side effects, we start patients on a low dose and work our way up. The figures show comparable rates of weight loss, regardless of the patient’s length of obesity. Regardless of their starting BMI, the second abstract shows comparable weight loss of 5, 10, 15, 20, and 25% of initial baseline weight, according to Lofton, who spoke with Medical News Today. Regardless of the patient’s starting BMI or length of obesity, I think this information can help prescribers decide that it’s never too late to treat an obese patient and that we have scientific proof to extrapolate the significant weight loss shown in the trials to our patients in a reasonable manner. Nevertheless, since each patient is unique, we must utilize our clinical judgment to identify the most appropriate course of treatment.

The companies that make Zepbound and Mounjaro, Eli Lilly and Company, provided funding for both the 2023 study and this new investigation. There’s always a chance of biases in studies that are sponsored by manufacturers, according to Ali. Still, I believe the results are reliable because multiple other studies have reached the same conclusion. As these studies are being reviewed by the FDA, I do not think that funding from Lilly has influenced these results because this subset analysis of a double-blind, placebo-controlled trial,” Lofton stated. “Data safety monitoring boards are also tasked with reviewing the studies, which were conducted by medical peers who are independent of the company.


Medications that have been suggested by doctors worldwide are available here

Leave a Reply

Your email address will not be published.